-
ALL
-
ALB
-
Asialaw
-
China Business Law Journal
-
China Law & Practice
-
Global Competition Review
-
IFLR1000
-
In-House Community
-
The American Lawyer
-
2023
-
2022
-
2021
-
2020
-
2019
-
2018
-
Previous Years
China Business Law Deals of the Year
- 2023
- Asia Innovations Group Limited on its IPO on the New York Stock Exchange through de-SPAC
- BeiGene on its A-share IPO on the SSE STAR Market, assisting it to become the first biotechnology company to be listed in Shanghai, Hong Kong and New York
- CALB on its H-share IPO on the SEHK, making it the first ever IPO of a power battery company on the SEHK
- MYSE in becoming the first private company to issue GDRs, list on the London Stock Exchange and be approved to use the “Green Economy Mark”
- Tianqi Lithium on its IPO, the largest to date on the SEHK in 2022
- Zhongtai Group in its successful issuance of the first Shanghai FTZ offshore bonds in the central and western regions of China
- Canada Pension Plan on the sale of its equity interest in Amcare Healthcare to ByteDance
- Investors on the capital increase of CGN Wind Power Corporation, the largest ever equity financing in the domestic new energy and power sector
- CPID on its acquisition of CPNE’s clean energy assets with a total installed capacity of 2.16 million KW
- Dongying court approved the reorganization plans of 20 companies including Dongying Fangyuan Nonferrous Metals Co., Ltd
- GAC Aion on its series A financing in the amount of RMB 18.3 billion, with a post-money valuation of more than RMB 100 billion
- Investors in their participation in the reorganization of Tsinghua Unigroup
- Temasek in the series C financing of Abogen Biosciences
- A syndicate led by Sumitomo Mitsui Banking Corporation in its successful granting of the first green syndicated loan in the domestic financial leasing industry – a breakthrough case in ESG finance
- INEOS on three major deals with Sinopec worth about USD 7 billion
- CPE with its investment in JD Property
- R&F Properties in completing the debt restructuring of the largest listed real estate company in Asia
- AstraZeneca in its invention patent infringement dispute with Aosaikang
- Golden Arches (China) in an environmental public interest litigation and comprehensively won the lawsuit
